Literature DB >> 21919622

Neisseria meningitidis B vaccines.

Donatella Panatto1, Daniela Amicizia, Piero Luigi Lai, Roberto Gasparini.   

Abstract

Invasive infections caused by Neisseria meningitidis are a serious public health problem worldwide and have a heavy economic impact. The incidence of invasive disease due to Neisseria meningitidis is highly variable according to geographical area and serogroup distribution. Since the introduction of vaccination programs with conjugated vaccine C in children and adolescents, most cases of invasive meningococcal disease in developed countries have been caused by meningococcus B. It is important to underline that invasive meningococcal disease will not be controlled until safe and effective vaccines for meningococcal B are available and widely used. The aims of this article are to describe the most recent developments in meningococcal B vaccines and to discuss how these vaccines can contribute to containing meningococcal disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21919622     DOI: 10.1586/erv.11.103

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  12 in total

1.  In silico analysis and modeling of ACP-MIP-PilQ chimeric antigen from Neisseria meningitidis serogroup B.

Authors:  Mehrdad Gholami; Alireza Salimi Chirani; Mona Moshiri; Mansour Sedighi; Abazar Pournajaf; Masoud Tohidfar; Gholamreza Irajian
Journal:  Rep Biochem Mol Biol       Date:  2015-10

Review 2.  An epidemiological review of changes in meningococcal biology during the last 100 years.

Authors:  Anne Abio; Keith R Neal; Charles R Beck
Journal:  Pathog Glob Health       Date:  2013-12-19       Impact factor: 2.894

Review 3.  Challenges and opportunities for meningococcal vaccination in the developing world.

Authors:  Rouba Shaker; Danielle Fayad; Ghassan Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2018-02-23       Impact factor: 3.452

4.  Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant.

Authors:  Abel E Vasquez; Ricardo A Manzo; Daniel A Soto; Magaly J Barrientos; Aurora E Maldonado; Macarena Mosqueira; Anastasia Avila; Jorge Touma; Elsa Bruce; Paul R Harris; Alejandro Venegas
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis Vaccines.

Authors:  R Gasparini; D Panatto; N L Bragazzi; P L Lai; A Bechini; M Levi; P Durando; D Amicizia
Journal:  J Immunol Res       Date:  2015-08-17       Impact factor: 4.818

6.  Mapping the laminin receptor binding domains of Neisseria meningitidis PorA and Haemophilus influenzae OmpP2.

Authors:  Noha M Abouseada; Mahde Saleh A Assafi; Jafar Mahdavi; Neil J Oldfield; Lee M Wheldon; Karl G Wooldridge; Dlawer A A Ala'Aldeen
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

7.  Molecular characterization of invasive Neisseria meningitidis strains isolated in Chile during 2010-2011.

Authors:  Gisselle N Barra; Pamela A Araya; Jorge O Fernandez; Jean-Marc Gabastou; Juan Carlos Hormazábal; Mabel Seoane; Paola C Pidal; Maria T Valenzuela; Ana Belén Ibarz-Pavón
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

8.  Phenotypic and genotypic characteristics of Neisseria meningitidis disease-causing strains in Argentina, 2010.

Authors:  Cecilia Sorhouet-Pereira; Adriana Efron; Paula Gagetti; Diego Faccone; Mabel Regueira; Alejandra Corso; Jean-Marc Gabastou; Ana Belén Ibarz-Pavón
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

Review 9.  Prospects for eradication of meningococcal disease.

Authors:  Simon Nadel
Journal:  Arch Dis Child       Date:  2012-09-15       Impact factor: 3.791

10.  Genotypic analysis of meningococcal factor h-binding protein from non-culture clinical specimens.

Authors:  Stephen A Clark; Jay Lucidarme; Lynne S Newbold; Ray Borrow
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.